Lantheus Reports Mixed Q1 2026 Results Amid Key Regulatory Wins
Event summary
- Q1 2026 revenue grew 1.2% YoY to $377.3M, with GAAP EPS up 76.5% to $1.80.
- PYLARIFY sales declined 6.5% YoY to $240.9M, while DEFINITY sales rose 6.8% to $84.6M.
- FDA approved PYLARIFY TruVu, with phased launch planned for Q4 2026.
- Achieved tentative FDA approval for PNT2003, a potential first radioequivalent for GEP-NETs.
- Divested SPECT business to SHINE for $31.4M, focusing on PET radiodiagnostics.
The big picture
Lantheus' Q1 2026 results reflect a mixed performance, with strong earnings growth offset by declining PYLARIFY sales. The company's strategic shift toward PET radiodiagnostics, coupled with key regulatory approvals, positions it for potential growth acceleration in 2027. However, the success of this transition hinges on the smooth execution of product launches and the effective monetization of its radiotherapeutic assets.
What we're watching
- Product Transition Risk
- The success of PYLARIFY TruVu's phased launch will depend on coding, coverage, and customer readiness.
- Regulatory Timeline
- The FDA extended the PDUFA date for LNTH-2501, potentially delaying its commercialization.
- Strategic Prioritization
- Lantheus' focus on radiodiagnostics and potential divestment of radiotherapeutic assets could reshape its long-term growth trajectory.
Related topics